Source: Eur Respir J 2016; 47:1727-1736
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Sitbon Olivier, Sattler Caroline, Bertoletti Laurent, Savale Laurent, Cottin Vincent, Jaïs Xavier, De Groote Pascal, Chaouat Ari, Chabannes Céline, Bergot Emmanuel, Bouvaist Hélène, Dauphin Claire, Bourdin Arnaud, Bauer Fabrice, Montani David, Humbert Marc, Simonneau Gérald. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 2016; 47:1727-1736

Member's Comments

No comment yet.

Related content which might interest you: Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020 Year: 2021 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Beyond a single pathway: combination therapy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 408-417 Year: 2016 Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Combined treatment in pulmonary hypertension Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Source: Eur Respir J 2014; 43: 1691-1697 Year: 2014 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011 Challenges in the diagnosis and treatment of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 313-320 Year: 2012 Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003